Gelonghui, April 9 | Gacos-B (01167.HK) announced that the company announced the pre-clinical evaluation results of the PARP7 inhibitor JAB-26766 and the p53 Y220C activator JAB-30355 in summary form at the 2024 American Association for Cancer Research (AACR) annual meeting to be held from April 5 to April 10, 2024.

JAB-26766 is an effective orally bioavailable PARP7 inhibitor. It is more than 1800 times more selective for PARP7 than PARP2. As a monotherapy, JAB-26766 has shown effective anti-tumor activity in vivo, and the anti-tumor effect can be further enhanced by combination with STING agonists or anti-PD-1 monoclonal antibodies.

Jab-30355 is a potent selective P53-Y220c activator. JAB-30355 showed dose-dependent antitumor activity, induced tumor growth stagnation or regression in multiple CDX and PDX models of ovarian cancer, pancreatic cancer, gastric cancer, and small cell lung cancer, and was well tolerated. JAB-30355 is undergoing phase i/IIa clinical trial in the US to evaluate the safety and efficacy of JAB-30355 in patients with advanced solid tumors.